RT Journal Article
SR Electronic
T1 A data-driven tool for tracking and predicting the course of COVID-19 epidemic as it evolves
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.28.20046177
DO 10.1101/2020.03.28.20046177
A1 Norden E. Huang
A1 Fangli Qiao
A1 Ka-Kit Tung
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.28.20046177.abstract
AB For an emergent disease, such as Covid-19, with no past epidemiological data to guide models, modelers struggle to make predictions of the course of the epidemic (1), and when predictions were made the results would vary widely. Yet much empirical information is already contained in the data of evolving epidemiological profiles. We show, for epidemics of low fatality rate, both empirically with data, and theoretically, how the ratio of daily infected and recovered cases can be used to track and predict the course of the epidemic. Ability to predict the turning points and the epidemic’s end is of crucial importance for fighting the epidemic and planning for a return to normalcy. The accuracy of the prediction of the peaks of the epidemic is validated using data in different regions in China showing the effects of different levels of quarantine. The validated tool can be applied to other countries where Covid-19 has spread, and generally to future epidemics. A preliminary prediction for South Korea is made with limited data, with end of the epidemic as early as the second week of April, surprisingly.SIGNIFICANCE We offer a practical tool, as an alternative to traditional models, for tracking and predicting the course of an epidemic using the daily data on the infection and recovery. This data-driven tool can predict the turning points two weeks in advance, with an accuracy of 2-3 days, validated using data from various regions in China selected to show the effects of quarantine. It also gives information on how rapid the rise and fall of the case numbers are. Although empirical, this approach has a sound theoretical foundation; the main components of the results are validated after the epidemic is near an end, as is the case for China, and therefore generally applicable to future epidemics of low fatality rate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding information.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are publicly available.